

# PROGRESS IN NUTRITION

*Journal of Nutrition and Internal Medicine*

Indexed in Science Citation Index Expanded (SciSearch®); Journal Citation Reports/Science Edition; Excerpta Medica/Embase, ISI Web of Science  
Impact Factor: 0,312

MATTIOLI 1885



---

# PROGRESS IN NUTRITION

JOURNAL OF NUTRITIONAL AND INTERNAL MEDICINE

---

Organo Ufficiale della Società Italiana di Scienza dell'Alimentazione (S.I.S.A.)  
Con il patrocinio dell'Associazione Ricercatori di Nutrizione e Alimenti (A.R.N.A.)

FONDATORE / FOUNDING EDITOR

Massimo Cocchi  
*Scottish Agricultural College, Edinburgh*

PRESIDENTE / PRESIDENT

Andrea Strata  
*Università di Parma*

DIRETTORE SCIENTIFICO / EDITOR

Leone Arsenio  
*Azienda Ospedaliera Universitaria di Parma*

DIRETTORE RESPONSABILE /  
DEPUTY EDITOR

Federico Cioni

COMITATO SCIENTIFICO / EXECUTIVE EDITORS

F. Arfini

*Università di Parma*

D. Atkinson

*Scottish Agricultural College, Edinburgh*

G. Ballarini

*Università di Parma*

S. Bernasconi

*Università di Parma*

R. Berni Canani

*Università di Napoli*

G. Bertoni

*Università di Piacenza*

S.E. Carlson

*Kansas City University*

E.L. Cavalieri

*University of Nebraska*

F. Di Lisa

*Università di Padova*

G. Fatati

*Università di Terni*

N.G. Frega

*Università di Ancona*

C. Galli

*Università di Milano*

C. Giacomini

*Università di Parma*

M. Gualerzi

*Direttore Sanitario Terme di Salsomaggiore e Tabiano, Parma*

G.M. Halpern

*Hong Kong Polytechnic University*

E.L. Iorio

*Presidente Osservatorio Internazionale dello  
Stress Ossidativo, Salerno*

T. Leighton

*Berkeley Università*

M.C. Mancini

*Università di Parma*

R. Marchelli

*Università di Parma*

P. Migliaccio

*Università Sapienza di Roma*

A.L. Mordenti

*Università di Bologna*

K. Mullis

*Premio Nobel per la Chimica 1993*

S.M. Nabavi

*Baqiyatallah University of Medical Sciences, Tebran, Iran*

F. Nicastro

*Università di Bari*

R.C. Noble

*Scottish Agricultural College of Edinburgh*

B. Palmieri

*Università degli Studi di Modena e Reggio Emilia*

G. Palmieri

*Primario Emerito Medicina Interna, Azienda Ospedaliera*

*Ospedale Niguarda Ca' Granda, Milano*

G. Riccardi

*Università di Napoli*

C.M. Rotella

*Università di Firenze*



PUBLISHER

Mattioli 1885 srl Casa Editrice  
Strada di Lodesana, 649/sx, Loc. Vaio  
43036 Fidenza (PR), Italy  
Tel. ++39 0524 530383  
Fax ++39 0524 82537  
E-mail: edit@mattioli1885.com  
www.progressinnutrition.it



## Mattioli 1885

srl- Strada di Lodesana 649/sx  
Loc. Vaio - 43036 Fidenza (Parma)  
tel 0524/530383  
fax 0524/82537  
www.mattioli1885.com

DIREZIONE GENERALE  
*Direttore Generale*  
Paolo Cioni  
*Vice Presidente e Direttore Scientifico*  
Federico Cioni

DIREZIONE EDITORIALE  
*Editing Manager*  
Anna Scotti  
*Editing*  
Valeria Ceci  
*Foreign Rights*  
Nausicaa Cerioli

MARKETING E PUBBLICITÀ  
*Direttore Commerciale*  
Marco Spina  
*Responsabile Area ECM*  
Simone Agnello  
*Project Manager*  
Natalie Cerioli  
Massimo Radaelli  
*Responsabile Distribuzione*  
Massimiliano Franzoni

PROGRESS IN NUTRITION  
Registrazione Tribunale di Parma  
N. 4 del 21/1/1999

Spedizione in abbonamento postale  
Abbonamento annuale euro 57

I dati sono stati trattati elettronicamente e utilizzati dall'editore Mattioli 1885 spa per la spedizione della presente pubblicazione e di altro materiale medico scientifico. Ai sensi dell'Art. 13 L. 675/96 è possibile in qualsiasi momento e gratuitamente consultare, modificare e cancellare i dati o semplicemente opporsi all'utilizzo scrivendo a: Mattioli 1885 srl - Casa Editrice, Strada della Lodesana 249/sx, Loc. Vaio, 43036 Fidenza (PR) o a [direct@mattioli1885.com](mailto:direct@mattioli1885.com)

Progress in Nutrition is indexed by: Science Citation Index Expanded (SciSearch®); Journal Citation Reports/Science Edition; Excerpta Medica/Embase, ISI Web of Science; Scopus

Impact Factor (released in June 2016): 0.312

# INDEX

Volume 18 / n. 4

December 2016

## Reviews

- 315 *Emanuele Sinagra, Dario Raimondo, Giancarlo Pompei, Gaetano Cristian Morreale, Francesca Rossi, Salvatore Marasà, Marco Calvaruso, Giuseppe Mastrocinque, Stefano Mandalà, Guido Martorana, Pier Enrico Marchesa, Aroldo Gabriele Rizzo, Georgios Amvrosiadis, Francesco Cappello, Francesco Carini, Giovanni Tomasello*  
Pouchitis: a tridimensional view
- 323 *Maryam Nouri, Ali Tarighat-Esfanjani*  
Mechanisms of breast feeding actions on obesity prevention: a systematic review

## Original articles

- 334 *Agostino Serra, Salvatore Cocuzza, Paola Di Mauro, Luisa Licciardello, Giacomo Spinato, S Gallina, Luigi Maiolino*  
Oxidative stress neuroinflammation and cellular stress response in sensorineural hearing loss: novel nutritional therapeutical approaches
- 344 *Müjgan Öztürk Arıkbuka, Sevinç Yücecan*  
Assessment of nutritional status and its association with anthropometric measurements, blood results and body composition in elderly cardiovascular patients
- 352 *Ilknur Aydın Avcı, Alaattin Altın, Pinar Sökülmez Kaya*  
The eating habits, consuming foods, and body mass index of elderly people registered in a family health center in Samsun
- 360 *Gülhan Samur, Özlem Özpak Akkuş, Gözde Ede, Aylin Ayaz, Ash Akyol Mutlu, Melih Akkuş, Nuri Danişman*  
Nutritional status among women with preeclampsia and healthy pregnant women
- 369 *Francesco Di Pierro, Giuliana Rapacioli, Alexander Bertuccioli*  
Role of a proprietary mixture of water-soluble, viscous fibers and phytosterols in managing overweight/obese subjects poorly following a prescribed diet and physical exercise regimen. Preliminary results
- 376 *Shaghayegh Hadizadeh Riseh, Majid Mobasseri, Mohammad-Asghari Jafarabadi, Mahdieh Abbasalizad Farhangi, Elham Ajorlou*  
Nutritional intakes, lipid profile and serum apo-lipoproteins concentrations and their relationship with antithyroid, antigliadin and anti-tissue transglutaminase antibodies in patients with Hashimoto's thyroiditis
- 385 *Margherita Gulino, Claudio Maggi, Caterina Strumia, Marcello Caputo, Anna Costa, Marina Mortara, Ilaria De Luca, Monica Minutolo, Cinzia Amelio, Alessandra Fornuto, Angelina Della Torre, Emiliano Antonioli, Bartolomeo Avataneo, Anna Aldrighetti, Ugo Tanti, Domenica Pata, Giuseppe Zicari*  
The celiac disease: risk management in foodservice

- 
- 396 *Claudio Maioli, Claudio Colosio, Fulvio Muzio, Federico Cioni*  
Aspetti nutrizionali dei pasti di una mensa per i poveri: l'esperienza dell'Opera di San Francesco di Milano, Italy
- 403 *Hamid Arazi, Azadeh Najafdari, Ehsan Eghbali*  
Effect of Big Bear energy drink on performance indicators, blood lactate levels and rating of perceived exertion in elite adolescent female swimmers
- 411 *Omer Kilib, Mehmet Ali Kutlu, Fethi Ahmet Ozdemir*  
Examination of the various chemical properties of the Hizan region (Bitlis-Turkey) honey types
- 421 *Mohamed Farouk ElSadek, Ali Madi Almajwal, Mahmoud Mustafa Ali Abulmeaty*  
Antioxidant effects of ginger, cinnamon and combination on Streptozotocin-induced hyperglycemia associated oxidative stress in rats
- 429 *Sahar Omidpanah, Mahdi Vazirian, Abbas Hadjiakhondi, Seyed Mohammad Nabavi, Azadeh Manayi*  
Evaluation of antibacterial activity of some medicinal plants against Isolated *Escherichia coli* from diseased laying hens
- 436 *Shofiul Azam, Prawej Ansari, Shahnaz Jalil, Abdunasir Hussain Ibrahim, Nasrin Sultana, Mohammad Mosharraf Hossain, Jaysee Muhammad Naveed, Mohammed Forhad Hossain*  
Antinociceptive activity investigation of the methanolic crude extract of *Costus speciosus* in Mice
- 443 *Salem M. Al-Amri, Khalid M Elhindi, Ahmed F. Sharaf El-Din*  
Effects of arbuscular mycorrhizal fungus *Glomus mosseae* and phosphorus application on plant growth rate, essential oil content and composition of coriander (*Coriander sativum* L.)
- 455 *Annarita Nicastro, Aldo Corriero, Francesco Nicastro, Davide De Marzo*  
Histological characteristics in *Longissimus thoracis* muscle of Italian and Polish crossbreed horse

## R E V I E W

## Pouchitis: a tridimensional view

*Emanuele Sinagra<sup>1,2,3</sup>, Dario Raimondo<sup>4</sup>, Giancarlo Pompei<sup>4</sup>, Gaetano Cristian Morreale<sup>5</sup>, Francesca Rossi<sup>1</sup>, Salvatore Marasà<sup>7</sup>, Marco Calvaruso<sup>8</sup>, Giuseppe Mastrocinque<sup>9</sup>, Stefano Mandalà<sup>10</sup>, Guido Martorana<sup>10</sup>, Pier Enrico Marchesa<sup>10</sup>, Aroldo Gabriele Rizzo<sup>4</sup>, Georgios Amvrosiadis<sup>5</sup>, Francesco Cappello<sup>3,6</sup>; Francesco Carini<sup>6</sup>, Giovanni Tomasello<sup>3,6</sup>*

<sup>1</sup>Gastroenterology & Endoscopy Unit, Fondazione Istituto San Raffaele - G. Giglio, Contrada Pietrapollastra Pisciotto 90015, Cefalù, Italy; <sup>2</sup>PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Italy; <sup>3</sup>Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy; <sup>4</sup>Pathology Unit, Fondazione Istituto San Raffaele - G. Giglio, Contrada Pietrapollastra Pisciotto 90015, Cefalù, Italy; <sup>5</sup>Gastroenterology & Hepatology Unit, DIBIMIS, AOUP Paolo Giaccone, University of Palermo, Piazza delle Cliniche 2, 90100, Palermo, Italy; <sup>6</sup>Department of Experimental Biomedicine and Clinical Neuroscience, Section of Human Anatomy, (BIONEC), University of Palermo, Italy; <sup>7</sup>Centro Diagnostico Marasà, Palermo, Italy; <sup>8</sup>Pathology Unit, Ospedali Riuniti "Villa Sofia - Cervello, University of Palermo, via trabucco 180, 90136 Palermo, Italy; <sup>9</sup>Urology Unit, AOUP Paolo Giaccone, University of Palermo, Piazza delle Cliniche 2, 90100, Palermo, Italy; <sup>10</sup>Surgery Unit, Fondazione Istituto San Raffaele - G. Giglio, Contrada Pietrapollastra Pisciotto 90015, Cefalù, Italy

**Summary.** The preferred surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis (FAP) is represented by proctocolectomy with ileal pouch-anal anastomosis (IPAA). However, patients with UC who have undergone IPAA are prone to develop several complications, which include surgery related/mechanical complications; inflammatory or infectious disorders; functional disorders; dysplasia or neoplasia; and systemic or metabolic disorders. Pouchitis, which is defined as the acute and/or chronic inflammation of the ileal reservoir, represents the most common long-term adverse sequela after IPAA. Gut microbiota play a pivotal role in the initiation and disease progression of pouchitis. Pouchitis can be classified according to the activity of the disease, the duration of the symptoms, the pattern of the disease or response to antibiotic therapy. Patients with IPAA for UC tend to experience a variety of symptoms, ranging from mild pelvic or perianal discomfort to a debilitating complex of symptoms that may eventually lead to pouch excision thereby necessitating the construction of a permanent ileostomy. To date, the etiology, the diagnosis and the medical management of pouchitis represent a clinical challenge. In fact pouchitis range from a disease with an acute antibiotic-responsive presentation to a chronic antibiotic-refractory form, with subsequent different disease mechanisms and clinical course. A tridimensional and multidisciplinary approach, including endoscopy, histology, and laboratory testing is widely helpful to identify the different phenotypes of the disease and to manage correctly its treatment.

**Key words:** pouchitis, ulcerative colitis, Intestinal Bowel Diseases, dysbiosis

### Epidemiology

The preferred surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis (FAP) is represented by proctocolectomy with ileal pouch-anal

anastomosis (IPAA), which could be considered a better alternative to proctocolectomy with permanent ileostomy, since it preserves intestinal continuity and sphincter function and removes the entire colorectal mucosa. The IPAA consists of total abdominal colec-



tomy, stripping of the rectal mucosa with preservation of the anal sphincter, and the construction of an ileal pouch that is anastomosed to the anus (1).

In the case of UC, up to 30% of affected patients will require surgical management of their disease because of medically intractable disease, fulminant course, dysplasia or cancer and even due to patient preference not to take medication on an indefinite timeline (1).

However, patients with UC who have undergone IPAA are prone to develop several complications, which include surgery related/mechanical complications; inflammatory or infectious disorders; functional disorders; dysplasia or neoplasia; and systemic or metabolic disorders (2).

Pouchitis, which is defined as the acute and/or chronic inflammation of the ileal reservoir, represents the most common long-term adverse sequela after IPAA (3).

According to some series approximately 50% of patients can be expected to experience at least one

episode of pouchitis. In a study of complications and long-term outcomes in 1310 patients who underwent IPAA for chronic UC, 559 patients had at least one episode of pouchitis (4). The cumulative risk of having at least one episode was 18% at 1 year after surgery and 48% at 10 years. Approximately 394 of the 559 patients who had at least one attack of pouchitis had a second episode. The cumulative probability of having a second episode after an initial attack within 2 years of IPAA was 64%.

Several studies show that most cases of pouchitis occur within the first few years after IPAA (5) while others, conversely, report that risk could continue to increase during further follow-up (6). Interestingly, pouchitis rarely occurs in patients who have IPAA for familial adenomatous polyposis (FAP) (7).

Several risk factors for pouchitis have been reported, although they have not been demonstrated consistently. Extensive or severe UC (8) backwash ileitis (9) extraintestinal manifestations of UC (10,11) pre-colectomy thrombocytosis (12,13) pANCA positivity (14,15) nonsmoking status, and nonsteroidal anti-inflammatory drug (NSAID) use (16-18) have all been reported as risk factors for the development of pouchitis.

However, there is little agreement in the literature as to which factors definitely increase a patient's

risk for pouchitis. This discrepancy could be due to duration and intensity of follow up after IPAA (19); diagnostic criteria of pouchitis used; stratification of pouchitis — acute *versus* chronic pouchitis or a combination of both (20); inclusion or exclusion of CD of the pouch (18) or cuffitis (21); and the number of patients studied (22).

## Classification

Pouchitis can be classified according to the activity of the disease, the duration of the symptoms, the pattern of the disease or response to antibiotic therapy. With regard to disease activity, pouchitis can be classified as in remission or mildly, moderately, or severely active, based on symptoms. With regard to duration, pouchitis can be classified as acute (<4 weeks) or chronic (more than 4 weeks). On the other hand, disease pattern can be classified as infrequent (1–2 acute episodes), relapsing (more than 3 acute episodes) or continuous. Relapsing pouchitis is also considered a form of chronic pouchitis. Finally, with regard to response to standard antibiotic therapy, pouchitis can be classified as responsive, dependent or refractory (23).

## Clinical features

Patients with IPAA for UC tend to experience a variety of symptoms, ranging from mild pelvic or perianal discomfort to a debilitating complex of symptoms that may eventually lead to pouch excision thereby necessitating the construction of a permanent ileostomy. Clinicians typically base their suspicion of pouchitis on a constellation of clinical symptoms such as: an increase in stool frequency, tenesmus, change in stool consistency, abdominal cramps and rectal bleeding. Treatment is often prescribed based on these clinical symptoms alone.

However, diagnosis of pouchitis based on symptoms alone has been shown to be non-specific due to the fact that symptoms can originate from a myriad of aetiologies, not necessarily inflammatory in nature.

## Etiology

Gut microbiota play a pivotal role in the initiation and disease progression of pouchitis (2).

The contribution of gut microbiota to the pathogenesis of pouchitis is multifaceted: firstly, through the dysbiosis (24-27) and therefore, through the emergence of pathogenic bacteria, fungi, or viruses (28). The role of dysbiosis in the pathogenesis of pouchitis is not yet fully clear, as it is in the field of inflammatory bowel disease (29)

The construction of the ileal reservoir provoke an altered bowel anatomy that can lead to fecal stasis and colonic metaplasia in the pouch body from the original ileal mucosa, thus creating an environment favourable to the development of inflammation (30).

Pathogen-associated pouchitis can occur in a subset of patients. *C. difficile* infection (CDI) is common in symptomatic patients with IPAA. Other pathogens have been reported to be associated with episodes of active pouchitis, including *C. perfringens*, *Campylobacter* species, group D streptococci (*Enterococcus* species), haemolytic strains of *E. coli*, and cytomegalovirus (CMV) infection (31-35). These pathogenic microbes detected in pouchitis patients with systemic symptoms may contribute to disease episodes or be responsible for a refractory course to conventional antibiotic therapy (2). Furthermore, such bacterial species may exert different impacts on innate and adaptive mucosal immune function.

Table 1 shows the mechanisms of involvement of innate and adaptive immunity in the pathogenesis of pouchitis.

## Work-up


At the initial occurrence of symptoms that might suggest a pouchitis, infectious aetiologies should be firstly ruled out, through stool for culture, *Clostridium difficile* toxin assay and cytomegalovirus tissutal polymerase chain reaction.

Once infectious aetiologies and other possible contributors have been excluded, pouch endoscopy should be performed. With regard to the opportunity to administer a trial of antibiotics as being both therapeutic and diagnostic of 'pouchitis', this practice should be avoided, because patients with pouch symptoms may respond quite rapidly to the administration of antibiotics without having evidence of the endoscopic or histological inflammation that is required to make a diagnosis of pouchitis.

On endoscopy, it is important: (a) to examine the pouch, the pre-pouch ileum and the rectal cuff; (b) the bioptic sampling of the pre-pouch ileum and the rectal cuff; (c) the evaluation of the endoscopic features of pouchitis, that may range from anywhere between minimal changes, including erythema, friability and mucus exudate to ulcers and bleeding.

**Table 1.** Involvement of innate immunity in the pathogenesis of pouchitis

Mechanisms through which innate immunity is involved in the pathogenesis of pouchitis	Mechanisms through which adaptive immunity is involved in the pathogenesis of pouchitis
Colonic metaplasia related-dysbiosis, with specific regard to production of sulfate-reducing bacteria	Increased proliferation of immature plasma cells
Alterations in mucin glycoproteins	Increased production of proinflammatory cytokines, such as TNF, and proinflammatory neuropeptides
Increased permeability of the gastrointestinal mucosa	Increased production of cell adhesion molecules
Aberrant expression of Toll-like receptors	Increased production of platelet-activating factor
Altered expression of Paneth-cell-specific human defensin-5	Increased production of lipoxygenase products of arachidonic acids
	Increased production of VEGF



**Figure 1.** Endoscopic view of the pouch inlet in a patient with mild pouchitis.

**Figure 2.** Another endoscopic view of the pouch inlet in a patient with mild pouchitis.

**Figure 3.** Endoscopic view of an healthy pre-pouch ileal mucosa.

**Figure 4.** This edge of colonic mucosa shows the characteristics of an inflammatory infiltrate of mild intensity: reduction of the glandular amount of the epithelium, almost disappearance of the secreting activity and distortion of the residual glandular elements, due to the compressive effect of the inflammatory infiltrate. Bar: 200 micra.

**Figure 5.** A greater enlargement in which we find the same morphological characteristics previously described: reduction of the glandular elements and presence of a polymorphous inflammatory infiltrate, consisting of lymphocytes, plasma cells and granulocytes. Bar: 200 micra.

**Figure 6.** This further enlargement underlines the marked amount of granulocytes (settling element for the diagnosis of an inflammatory bowel disease), and shows also a certain degree of intraepithelial involvement from the inflammatory elements towards the glands. To notice some apoptotic nuclei at the base of the glandular elements. Bar: 200 micra.

**Figure 7.** Endoscopic view of the pouch inlet in a patient with severe pouchitis

**Figure 8.** Another endoscopic view of the pouch inlet in a patient with severe pouchitis

**Figure 9.** Endoscopic view of an inflamed pre-pouch ileal mucosa in a patient with severe pouchitis

**Figure 10.** In this second case, the intensity of the inflammatory infiltrate can be classified as severe. The inflammatory infiltrate, besides colonizing the proper foil giving all those morphological modifications described in Fig. 4, extends him to also involve the muscularis mucosae, transmurally. Bar: 200 micra.

**Figure 11.** In this greater enlargement it can be observed the total disappearance of the glandular amount of the epithelium, entirely replaced by the ulcerative inflammation. Bar: 200 micra.

**Figure 12.** Also in this figure, the eosinophylic component is preponderant. The polymorphous inflammatory infiltrate distorts and reduces in dimensions the small residual glands. Bar: 200 micra.

Two composite scores are used to the diagnostic and prognostic assessment of pouchitis. These are the pouchitis disease activity index (PDAI) (36) and the pouchitis activity score (PAS) (37)

In the first one, an overall score is calculated from three separate sixpoint scales including clinical symptoms, endoscopic findings and histological changes. Furthermore, the PDAI incorporates histological features of acute inflammation, and establishes a cut-off for differentiation between 'pouchitis' ( $\geq 7$  points) and 'no pouchitis' ( $< 7$  points).

On the other hand, the PAS includes findings similar to those of the PDAI but also comprises the histological features of chronic inflammation, distin-

guishing three grades of pouch inflammation: mild adaptive, moderate pouchitis and severe pouchitis.

Recently, Elder and coworkers evaluated the endoscopic features associated with ileal pouch features (38). The authors concluded that distorted appearance of "beak" portion of owl's eyes along with Crohn's disease of the pouch or surgery-related complications, postoperative use of biologics, and persistent cuffitis were the risk factors associated with pouch failure, and that the assessment of endoscopic owl's eye structure may provide an additional clue to predict pouch outcome (38).

Histological assessment will focus on acute inflammatory infiltrates, however also dysplastic changes



should be ruled out in the rare case of progression to malignant transformation.

Abdominal and pelvic CT scan, pelvic MRI, perineal or transanal ultrasound, pouchography or examination under anaesthesia are requested in the case of signs of inflammation, fistulas, leaks or abscesses.

## Medical management

Antibiotics showed widely their effectiveness in treating pouchitis (39). Oral metronidazole (at a dose of 1 to 2 g daily) (40,41) and oral ciprofloxacin (at a dose of 1 g daily) are an effective treatment for pouchitis (42,43). Treatment may be most effective with acute episodes, and was found to be less effective in patients with a chronic course of the disease.

Oral metronidazole, in a double-blind cross-over randomised trial, was associated with a significant reduction in stool frequency by three movements per day (versus an increase of one per day with placebo) even if absence of changes in the endoscopic or histologic grade of inflammation (39).

In another randomized trial consisting of 16 patients, assigned to either ciprofloxacin 1 g/day or metronidazole 20 mg/kg per day, a response to both drugs was showed, but a better improvement and fewer side effects (0 versus 33 percent) were found with ciprofloxacin (42)

For this reason, ciprofloxacin at 1 g daily is primarily used as the initial treatment for acute pouchitis, therefore reserving metronidazole for patients in which ciprofloxacin fails.

Rifaximin has also been used in pouchitis, even if it was not more effective than placebo in a small controlled trial (44). However, rifaximin maintenance therapy was effective in preventing relapse in 65 percent of patients with antibiotic-dependent pouchitis after induction of remission with a variety of antibiotics (45).

On the other hand, a combined approaches, including ciprofloxacin and rifaximin (46,47) metronidazole and ciprofloxacin (48) and ciprofloxacin and tinidazole (49) have also been found to be efficacious in the treatment of chronic refractory pouchitis (50).

Interestingly, in a study performed by McLaughlin and coworkers, fecal coliform sensitivity testing was showed to be helpful in clarifying the choice of effective

antibiotics in patients with antibiotic-resistant pouchitis (51), allowing to achieve a clinical remission through an individualized therapy in 80 percent of patients.

In the case of antibiotic failure, budesonide may be a treatment option. Oral budesonide (9 mg/day for eight weeks) was effective in a series of patients with acute pouchitis refractory to antibiotics (52).

Budesonide suppositories for four weeks showed endoscopic improvement or remission at the end of the treatment in all patients with acute pouchitis (53), even if with a high degree of early recurrence. In another controlled trial, 26 patients were randomly assigned to budesonide enemas (2 mg per 100 mL at bedtime) plus placebo tablets or oral metronidazole (500 mg twice daily) plus placebo enemas (54). Both the treatment were associated with a clinical improvement but adverse effects were more common in patients receiving metronidazole.

With regards to probiotics, trials about the treatment of mild/moderate pouchitis are few, with small numbers of adult patients (55). To date, there is limited evidence for a role of probiotics as monotherapy for mild to moderate pouchitis at the present time, as showed by the trials performed by Kuisma, Laake and Gionchetti (56,57). On the other hand, two trials have studied whether there is an advantage to initiate probiotics immediately following ileal pouch-anal anastomosis to evaluate the eventual delay in onset of development of pouchitis (58,59).

Furthermore, small controlled trials have also suggested that at least one probiotic preparation (VSL#3™) may be effective in prevention of recurrent pouchitis after antibiotic induction of remission (60-63)

On the basis of the aforementioned data, clinical practice guidelines on management of pouchitis (64) suggested either VSL#3™ or chronic use of antibiotics for those patients with prompt recurrence of pouchitis following antibiotic usage or having multiple recurrences of pouchitis despite antibiotics, but does not suggest probiotics for acute treatment of pouchitis.

Glucocorticoid and/or mesalamine enemas followed by a short course of oral steroids if enemas cannot be retained can be used as a therapeutic trial (65) Infliximab was effective long-term (20 months) in IPAA patients with refractory luminal inflammation and in three of seven patients with pouch fistulas (66).

However, risks and benefits need to be considered; and this treatment (such also the treatment with 6-mercaptopurine or azathioprine) is likely reserved for patients with the most severe symptoms.

## Perspectives and conclusions

On the basis of the aforementioned data, we can deduce that microbiota play a pivotal role in the pathogenesis of pouchitis. Conversely, the investigation of the role of gut microbiota in the etiopathogenesis of pouchitis has been difficult because most of gut bacteria are not culturable (67).

In fact molecular microbiology techniques for the qualitative and quantitative measurement of microbiota are expensive and labor-intensive, particularly for the identification of the individual responsible bacteria. Therefore, the interpretation of the microbiota changes in cross-sectional studies comparing healthy and diseased pouches results challenging.

Due to the dysbiosis, despite intermittent or chronic antibiotic therapy or probiotic therapy, an abnormal mucosal immune response lead to chronic pouchitis or chronic antibiotic-refractory pouchitis. Furthermore, patients with genetic susceptibility (such as those with a NOD2/CARD15 mutation) and/or systemic immune-mediated disorders (such as PSC, IgG4-associated systemic disorders) result mainly exposed to the development of chronic antibiotic-refractory pouchitis. A molecular classification of pouchitis, with a combined assay of immunogenetic, serologic, and clinical markers, should be advisable (2).

As a consequence, patients with IPAA should be monitored closely. Pouchoscopy is the best way to monitor the anatomic status of the pouch, the degree of inflammation, and the structural abnormalities. For patients with the endoscopic finding of diffuse pouchitis and diffuse enteritis of the afferent limb, immune-mediated pouchitis/enteritis should be considered.

For patients with pouch inflammation that is distributed asymmetrically and has a clear demarcation of inflamed and noninflamed parts of the pouch body, ischemic pouchitis should be suspected.

When pouchoscopy shows abnormalities such as strictures, fistulas, and sinuses, CD of the pouch should

be suspected, therefore abdominal and pelvic imaging or examination under anaesthesia are often requested.

In patients with typical symptoms (increased bowel frequency, watery stools, or urgency) antidiarrheal agents can be used first. If the symptoms do not improve in few days, the patient should be evaluated and in some cases treated empirically with antibiotics.

A prolonged course of dual antibiotic therapy may help induce remission in patients with chronic antibiotic-refractory pouchitis. On the other hand, oral or topical mesalamine agents and a topically active corticosteroid agent (such as budesonide) are the preferred first-line drugs for immune-mediated pouchitis/enteritis. Second-line therapies include immunosuppressants (such as 6-mercaptopurine/azathioprine, methotrexate, tacrolimus), or anti-TNF agents.

To date, the aetiology, the diagnosis and the medical management of pouchitis represent a clinical challenge. In fact pouchitis range from a disease with an acute antibiotic-responsive presentation to a chronic antibiotic-refractory form, with subsequent different disease mechanisms and clinical course. A tridimensional and multidisciplinary approach, including endoscopy, histology, and laboratory testing is widely helpful to identify the different phenotypes of the disease and to manage correctly its treatment.

## References

1. Steinhart AH, Ben Bassat O. Pouchitis: a practical guide. *Frontline Gastroenterol* 2013;4:198-204
2. Shen B. Pouchitis: what every gastroenterologist needs to know. *Clin Gastroenterol Hepatol*. 2013 Dec;11(12):1538-49
3. Shen B. Diagnosis and Management of Postoperative Ileal Pouch Disorders. *Clin Colon Rectal Surg*. Dec 2010; 23(4): 259-268
4. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. *Br J Surg* 1998;85:800-803
5. Shepherd NA, Hulten L, Tytgat GN, et al. Workshop: Pouchitis. *Int J Colorectal Dis* 1989; 4: 205-29.
6. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. *World J Surg* 2000; 24: 851-6.
7. Sandborn WJ. Pouchitis: Definition, Risk Factors, Frequency, Natural History, Classification and Public Health Perspective. In: McLeod RS (ed) *Trends in Inflammatory Bowel Disease*

- Therapy, 1996. Hingham, MA, USA: Kluwer Academic Publishers, 1997.
8. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. *Ann Surg*. 1995;222: 120–127.
  9. Schmidt CM, Lazenby AJ, Hendrickson RJ, et al. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. *Ann Surg*. 1998; 227:654–662; discussion 63–65.
  10. Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. *Ann Surg*. 1990;211:622–627; discussion 7–9.
  11. Hata K, Watanabe T, Shinozaki M, et al. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. *Scand J Gastroenterol*. 2003;38: 1055–1058.
  12. Okon A, Dubinsky M, Vasiliauskas EA, et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. *Am Surg*. 2005;71: 821–826.
  13. Lian L, Fazio VW, Lavery IC, et al. Evaluation of association between pre colectomy thrombocytosis and the occurrence of inflammatory pouch disorders. *Dis Colon Rectum*. 2009;52:1912–1918.
  14. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. *Gut*. 2001;49:671–677.
  15. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. *Clin Gastroenterol Hepatol*. 2008;6:561–568.
  16. Fleshner P, Ippoliti A, Dubinsky M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. *Clin Gastroenterol Hepatol*. 2007;5: 952–958; quiz 887.
  17. Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. *Clin Gastroenterol Hepatol*. 2005;3:60–66.
  18. Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. *Am J Gastroenterol*. 2005;100:93–101.
  19. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomosis. *World J Surg* 2000;24:851–6.
  20. Fazio VW, Tekkis PP, Remzi FH, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. *Ann Surg* 2003;238:605–17.
  21. Lavery IC, Sirimarco MT, Ziv T, et al. Anal canal inflammation after ileal pouch-anal anastomosis. The need for treatment. *Dis Colon Rectum* 1995;38:803–6.
  22. Shen B, Fazio WG, Remzi FH, Lashner BA, Clinical Approach to Diseases of Ileal Pouch-Anal Anastomosis. *Am J Gastroenterol* 2005;100:2796–2807
  23. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. *Aliment Pharmacol Ther* 23, 1087–1096
  24. Duffy M, O'Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. *Dis Colon Rectum* 2002;45:384–388.
  25. Nasmyth DG, Godwin PG, Dixon MF, et al. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. *Gastroenterology* 1989;96:817–824.
  26. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. *Clin Gastroenterol Hepatol* 2007;5:352–360.
  27. Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? *Inflamm Bowel Dis* 2008;14:858–867.
  28. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. *Clin Gastroenterol Hepatol* 2008;6:782–788.
  29. Lim M, Sagar P, Finan P, et al. Dysbiosis and pouchitis. *Br J Surg* 2006;93:1325–1334.
  30. Scarpa M, Grillo A, Faggian D, et al. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. *Surgery* 2011;150:56–67.
  31. Shen B. Campylobacter infection in patients with ileal pouches. *Am J Gastroenterol* 2010;105:472–473.
  32. Ingram S, McKinley JM, Vasey F, et al. Are inflammatory bowel disease (IBD) and pouchitis a reactive enteropathy to group D streptococci (enterococci)? *Inflamm Bowel Dis* 2009;15: 1609–1610.
  33. Gosselink MP, Schouten WR, van Lieshout LM, et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. *Dis Colon Rectum* 2004;47:1519–1525.
  34. Muñoz-Juarez M, Pemberton JH, Sandborn WJ, et al. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as a refractory idiopathic chronic pouchitis: report of two cases. *Dis Colon Rectum* 1999;42:117–120.
  35. Moonka D, Furth EE, MacDermott RP, et al. Pouchitis associated with primary cytomegalovirus infection. *Am J Gastroenterol* 1998;93:264–266.
  36. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. *Mayo Clin Proc* 1994;69:409–15.
  37. Heuschen UA, Allemeyer EH, Hinz U, et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. *Dis Colon Rectum* 2002;45:776–88.
  38. Elder K, Lopez R, Kiran RP, Remzi FH, Shen B. Endoscopic features associated with ileal pouch failure. *Inflamm Bowel Dis*. 2013 May;19(6):1202-9.
  39. Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. *Expert Rev Gastroenterol Hepatol* 2009; 3:547
  40. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis.

- sis: definition, pathogenesis, and treatment. *Gastroenterology* 1994; 107:1856.
41. Dozois RR, Goldberg SM, Rothenberger DA, et al. Restorative proctocolectomy with ileal reservoir. *Int J Colorectal Dis* 1986; 1:2.
  42. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. *Dig Dis Sci* 1994; 39:1193.
  43. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis* 2001; 7:301.
  44. Gosselink MP, Schouten WR, van Lieshout LM, et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. *Dis Colon Rectum* 2004; 47:1519. Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. *Inflamm Bowel Dis* 2007; 13:1250.
  45. Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. *BMC Gastroenterol* 2008; 8:26.
  46. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. *Aliment Pharmacol Ther* 1999; 13:713.
  47. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. *Colorectal Dis* 2005; 7:182.
  48. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. *Aliment Pharmacol Ther* 2002; 16:909.
  49. Tremaine WJ, Sandborn WJ, Wolff BG, et al. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. *Aliment Pharmacol Ther* 1997; 11:1041.
  50. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. *Dis Colon Rectum* 2007; 50:498.
  51. McLaughlin SD, Clark SK, Shafi S, et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. *Clin Gastroenterol Hepatol* 2009; 7:545.
  52. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. *Aliment Pharmacol Ther* 2007; 25:1231.
  53. Belluzzi A, Campieri M, Miglioli M, et al. Evaluation of logistic pattern in "pouchitis" before and after the treatment with budesonide suppositories (abstract). *Gastroenterology* 1992; 102:A593.
  54. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. *Aliment Pharmacol Ther* 2002; 16:27.
  55. Sinagra, E., Tomasello, G., Cappello, F., Leone, A., Cottone, M., Bellavia, M., et al. (2013). Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. *J Biol Regul Homeost Agents*, 4(27(4)), 919-933.
  56. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of *Lactobacillus rhamnosus* GG on ileal pouch inflammation and microbial flora. *Aliment Pharmacol Ther* 2003; 17:509515.
  57. Laake KO, Bjorneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, Vatn MH. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configuration ileal-pouch-anal-anastomosis in ulcerative colitis. *Scand. J. Gastroenterol.* 2005; 40:43-51.
  58. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo, D, Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. *Inflamm. Bowel. Dis.* 2008; 14: 662-68.
  59. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini, G, Campieri M. High-dose probiotics for the treatment of active pouchitis. *Dis. Colon Rectum* 2007, 50, 2075-2078.
  60. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; 124: 12021209.
  61. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 2004; 53: 108114.
  62. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; 124: 12021209.
  63. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. *Aliment. Pharmacol. Ther.* 2005; 22:721-28.
  64. Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. *Inflamm. Bowel. Dis.* 2009; 15:1424-1431.
  65. Miglioli M, Barbara L, Di Febo G, et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. *N Engl J Med* 1989; 26:320.
  66. Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease related complications of the pouch: a Belgian case series. *Inflamm Bowel Dis* 2010; 16:243.
  67. Zoetendal EG, Rajilic-Stojanovic M, De Vos WM. High-throughput diversity

Correspondence:  
Giovanni Tomasello  
E-mail: giovanni.tomasello@unipa.it